Is Sangamo Therapeutics Pointing Toward Success? – Seeking Alpha
|
Is Sangamo Therapeutics Pointing Toward Success?
Seeking Alpha Sangamo Therapeutics (SGMO) is a $650 million dollar market cap company focused on gene and cell therapies, including conducting the first-ever genome editing studies in clinical trials. The company uses gene therapy, genome editing, cell therapy, and … |
